Trimetazidine acting as a metabolic agent reduces symptomatic and silent ischemia – the total ischemic burden. Its cellular action in improving myocardial metabolism is cardioprotective and may explain the improvement in left ventricular function seen in the failing heart as a result of its use. The metabolic approach to myocardial ischemia is becoming increasingly important, with symptomatic a...

Trimetazidine, a metabolic agent, acts at the cellular level to improve myocardial metabolism at the time of ischemia. A recent Cochrane Collaboration review of its use in stable angina has confirmed its effectiveness in reducing anginal attacks and nitrate consumption, at the same time as improving exercise performance with minimal adverse events. Additional reports identifying improved left v...

Abstract Introduction Impaired myocardial mitochondrial function plays an import role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF). Left ventricular relaxation has a high energy demand, and there is evidence indicative causal relationship between observed impaired homeostasis diastolic dysfunction. Improvement metabolism-modulating drugs may be promising nove...